Expression of the common acute lymphoblastic leukemia antigen (CD10) in mesenchymal tumors

Article Abstract:

The frequency of the CD10 antigen (the chemical pattern on the surface of acute lymphoblastic leukemia cells by which disease-fighting antibodies identify them) in benign (non-cancerous) and malignant (cancerous) tumors was investigated. The tumors examined were in tissues that developed from mesenchymal cells, the network of cells in the embryo that develops into the body's connective tissues, blood and lymph vessels (return white blood cells from body tissues to the blood). Fifty-five of the tumors were malignant and 26 were benign. CD10 antigen was found in: four out of four benign smooth muscle tumors (leiomyomas), seven out of 10 closely-packed fibrous tumors of smooth muscle tissue (leiomyosarcomas), one out of six malignant tumors of striated muscle tissue (rhabdomyosarcomas), one of two fibrous tumors (fibromatoses), one of three closely packed fibrous tumors (fibrosarcomas), one of four malignant closely packed fibrous tumors of the joints (synovial sarcomas), one of one tumor consisting of yellow nodules on the sheaths of the tendons (giant cell tumor of tendon sheath), three of three malignant tumors of bone marrow (Ewing's sarcomas), and two of three bone sarcomas (osteosarcomas). Furthermore, CD10 antigen was consistently found in the lining of the muscles in 12 fibrous tumors (fibroadenomas) and, in seven of these, was probably located in the cells of the muscle fibers. The following tumors were consistently free of CD10 antigen: tumors of fat tissue (lipomas, liposarcomas), nerve bundles (ganglioneuromas, ganglioneuroblastomas, neuroblastomas), certain types of nerves outside the brain and spinal cord (schwannomas) and tumors of disputed origin. Single cases of a fibrous tissue tumor (fibroma) and of a tumor of cartilage cells (chondrosarcoma) were also free of CD10. It was concluded that, although CD10 antigen is a frequent but not universal feature of mesenchymal tumors, it is of value in forming a correct diagnosis.

Analysis, Statistics, Connective tissue cells, Tissue specific antigens, CEA (Oncology), Carcinoembryonic antigen

---

Mesenchymal hamartoma of liver: a regional ischemic lesion of a sequestered lobe

Article Abstract:

Mesenchymal hamartoma of the liver appears to arise from the abnormal formation of a single blood vessel to a given lobule of the liver. Mesenchymal hamartoma of the liver refers to a benign, tumor-like growth of cells that is found mostly in children. Case studies of three children with mesenchymal hamartoma and one child with torsion of an accessory liver lobe revealed common patterns of lesion formation. Two of the masses removed clearly showed that blood supply to the lesion was from one large artery with no veins connecting them to the liver lobule. The characteristic blood vessel changes appear to be in response to an insufficient blood supply, usually the result of a blood clot. These findings support previous studies which suggested that mesenchymal hamartoma is not a tumor, but a reaction to a change in the blood supply to part of the liver.

Case studies, Liver diseases, Hamartoma

---

Pegaspargase for acute lymphoblastic leukemia

Article Abstract:

Pegaspargase appears to be safe in treating acute lymphoblastic leukemia (ALL) in patients who have developed allergies to asparaginase. Pegaspargase is sold by Rhone-Poulenc Rorer under the name Oncaspar. ALL is often effectively treated with a multi-drug regimen that includes asparaginase. However, some patients are allergic to asparaginase. Many patients who have allergic reactions to asparaginase appear to be able to tolerate pegaspargase. However, pegaspargase may also cause allergic reactions in about 30% of patients allergic to Escherichia coli asparaginase. Patients should receive 2500 units per meter squared of pegaspargase every 14 days. There have been no trials published that compared the effectiveness of pegaspargase and asparaginase.

Evaluation, Product/Service Evaluation, Chemotherapy, Lymphocytic leukemia, Oncaspar (Medication)

Similar abstracts:

• Abstracts: The medicine of the lateral pass. Rituals and roles in medical practice
• Abstracts: Emergency planning and the acute toxic potency of inhaled ammonia. Effects of electromagnetic fields on photophasic circulating melatonin levels in American kestrels
• Abstracts: Dalteparin - another low-molecular-weight heparin. Improvement in heparin prophylaxis. Heparin cofactor II-proteinase reaction products exhibit neutrophil chemoattractant activity
• Abstracts: Myospherulosis complicating wound healing. A hypothetical explanation for the aging of skin. Chronologic alteration of the three-dimensional arrangement of collagen and elastic fibers in connective tissue

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.